Compare IIPR & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | ARDX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | IIPR | ARDX |
|---|---|---|
| Price | $46.18 | $6.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $74.67 | $12.95 |
| AVG Volume (30 Days) | 219.1K | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 16.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $22.44 |
| Revenue Next Year | $1.70 | $34.00 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.58 | $3.50 |
| 52 Week High | $74.92 | $8.40 |
| Indicator | IIPR | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 41.88 |
| Support Level | $45.20 | $6.92 |
| Resistance Level | $46.56 | $7.43 |
| Average True Range (ATR) | 1.16 | 0.31 |
| MACD | -0.16 | -0.15 |
| Stochastic Oscillator | 26.35 | 9.51 |
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.